OncoCyte Income from Continuous Operations 2014-2024 | OCX
OncoCyte income from continuous operations from 2014 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
| OncoCyte Annual Income from Continuous Operations (Millions of US $) |
|
|---|---|
| 2023 | $-25 |
| 2022 | $-19 |
| 2021 | $-44 |
| 2020 | $-30 |
| 2019 | $-22 |
| 2018 | $-16 |
| 2017 | $-19 |
| 2016 | $-11 |
| 2015 | $-9 |
| 2014 | $-5 |
| 2013 | $-3 |
| OncoCyte Quarterly Income from Continuous Operations (Millions of US $) |
|
|---|---|
| 2024-09-30 | $-13 |
| 2024-06-30 | $-5 |
| 2024-03-31 | $-9 |
| 2023-12-31 | $-16 |
| 2023-09-30 | $-6 |
| 2023-06-30 | $-8 |
| 2023-03-31 | $6 |
| 2022-12-31 | $-12 |
| 2022-09-30 | $-2 |
| 2022-06-30 | $-1 |
| 2022-03-31 | $-3 |
| 2021-12-31 | $-15 |
| 2021-09-30 | $-14 |
| 2021-06-30 | $-10 |
| 2021-03-31 | $-4 |
| 2020-12-31 | $-6 |
| 2020-09-30 | $-7 |
| 2020-06-30 | $-9 |
| 2020-03-31 | $-8 |
| 2019-12-31 | $-8 |
| 2019-09-30 | $-5 |
| 2019-06-30 | $-5 |
| 2019-03-31 | $-4 |
| 2018-12-31 | $-5 |
| 2018-09-30 | $-3 |
| 2018-06-30 | $-5 |
| 2018-03-31 | $-4 |
| 2017-12-31 | $-4 |
| 2017-09-30 | $-7 |
| 2017-06-30 | $-4 |
| 2017-03-31 | $-5 |
| 2016-12-31 | $-3 |
| 2016-09-30 | $-3 |
| 2016-06-30 | $-3 |
| 2016-03-31 | $-3 |
| 2015-12-31 | $-4 |
| 2015-09-30 | $-2 |
| 2015-06-30 | $-1 |
| 2015-03-31 | $-1 |
| 2014-12-31 | |
| 2013-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $0.046B | $0.002B |
| OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $93.361B | 11.58 |
| Cencora (COR) | United States | $48.280B | 17.81 |
| DiDi Global (DIDIY) | China | $22.212B | 0.00 |
| Natera (NTRA) | United States | $22.082B | 0.00 |
| ICON (ICLR) | Ireland | $17.675B | 15.74 |
| Viatris (VTRS) | United States | $15.958B | 4.92 |
| Avantor (AVTR) | United States | $14.143B | 21.20 |
| Revvity (RVTY) | United States | $13.634B | 23.68 |
| CochLear (CHEOY) | Australia | $12.777B | 0.00 |
| Solventum (SOLV) | United States | $12.233B | 0.00 |
| BioMerieux (BMXMF) | France | $11.895B | 0.00 |
| Medpace Holdings (MEDP) | United States | $10.498B | 29.58 |
| Charles River Laboratories (CRL) | United States | $10.011B | 19.34 |
| HealthEquity (HQY) | United States | $9.104B | 49.41 |
| Doximity (DOCS) | United States | $8.999B | 52.97 |
| Sonic Healthcare (SKHHY) | Australia | $8.862B | 0.00 |
| Bausch + Lomb (BLCO) | Canada | $6.892B | 32.08 |
| Life Times (LTH) | United States | $5.081B | 33.63 |
| Organon (OGN) | United States | $3.935B | 3.97 |
| Sotera Health (SHC) | United States | $3.631B | 19.42 |
| BrightSpring Health Services (BTSG) | United States | $3.265B | 69.44 |
| Surgery Partners (SGRY) | United States | $2.925B | 33.35 |
| Concentras Parent (CON) | United States | $2.789B | 0.00 |
| PACS (PACS) | United States | $2.515B | 0.00 |
| Alignment Healthcare (ALHC) | United States | $2.310B | 0.00 |
| Ardent Health Partners (ARDT) | United States | $2.259B | 0.00 |
| Premier (PINC) | United States | $2.195B | 11.42 |
| GeneDx Holdings (WGS) | United States | $2.162B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.995B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.868B | 49.00 |
| Teladoc Health (TDOC) | United States | $1.828B | 0.00 |
| Progyny (PGNY) | United States | $1.315B | 26.62 |
| Pediatrix Medical (MD) | United States | $1.285B | 12.57 |
| CareDx (CDNA) | United States | $1.241B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.206B | 0.00 | |
| AMN Healthcare Services Inc (AMN) | United States | $0.984B | 6.66 |
| Embecta (EMBC) | United States | $0.797B | 5.32 |
| QDM (QDMI) | Hong Kong, SAR China | $0.790B | 0.00 |
| Agilon Health (AGL) | United States | $0.779B | 0.00 |
| SBC Medicals (SBC) | United States | $0.674B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.662B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.522B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.474B | 0.00 |
| DocGo (DCGO) | United States | $0.434B | 16.35 |
| Enhabit (EHAB) | United States | $0.380B | 32.87 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.302B | 0.00 |
| ModivCare (MODV) | United States | $0.254B | 13.79 |
| LifeMD (LFMD) | United States | $0.251B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.221B | 0.00 |
| Biodesix (BDSX) | United States | $0.186B | 0.00 |
| Nutex Health (NUTX) | United States | $0.179B | 0.00 |
| Beauty Health (SKIN) | United States | $0.176B | 0.00 |
| MultiPlan (MPLN) | United States | $0.112B | 0.00 |
| So-Young (SY) | China | $0.086B | 16.60 |
| Ascend Wellness Holdings (AAWH) | United States | $0.085B | 0.00 |
| Singular Genomics Systems (OMIC) | United States | $0.054B | 0.00 |
| NeueHealth (NEUE) | United States | $0.041B | 1.10 |
| IceCure Medical (ICCM) | Israel | $0.032B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.032B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.031B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.021B | 0.00 |
| Oncology Institute (TOI) | United States | $0.012B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.009B | 0.00 |
| XWELL (XWEL) | United States | $0.008B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.007B | 0.00 |
| KindlyMD (KDLY) | United States | $0.006B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| ISpecimen (ISPC) | United States | $0.004B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.001B | 0.00 |